Product category:
Chemical modelling software
News Release from: Quantum Pharmaceuticals
Edited by the Laboratorytalk Editorial
Team on 15 September 2004
Developing revolutionary drug discovery
product
Combines leading in silico lead optimisation technology with the synthetic and natural compound libraries and network of scientists to create lead libraries
InterBioScreen (IBS), provider of unique chemical compound libraries, and Quantum Pharmaceuticals, high-tech drug discovery company, have announced a new project to create a revolutionary product for the drug discovery market The joint project, QuantumLead, combines the in silico lead optimisation technology of Quantum Pharmaceuticals with the unique synthetic and natural compound libraries and network of scientists of IBS to create Q-Lead-Libraries
This article was originally published on Laboratorytalk on 10 Oct 2006 at 8.00am (UK)
Related stories
Software simplifies LogP calculation
Predicts octanol-water partition coefficient, LogP, for any small organic molecule, calculates LogD for dissociative systems at a given pH, and estimates drug-likeness
Software 'will irrevocably change' drug discovery
Drug discovery software for Linux and Windows is designed to enhance stages of drug discovery workflows such as target and drug hit identification, lead identification and lead optimisation
Q-Lead-Libraries are libraries of compounds, which are ranked according to their constant affinity to particular protein targets.
They are designed to allow biotech and pharmaceutical companies to achieve a dramatic acceleration of the drug discovery R and D process by reducing or eliminating the time involved in screening and optimisation of hits and leads.
Using Q-Lead-Libraries will enable biotech and pharmaceuticals companies to find exclusive novel drug candidates more quickly and at a lower cost.
The technology behind Q-Lead-Libraries is Quantum Pharmaceuticals's proprietary intermolecular modeling tools and accurate affinity calculations.
The technology provides for full flexibility of both ligands and proteins and takes into account all factors of binding free energy including solvation effects, Van Der Waals energy in solution, as well as electrostatic and entropy contribution.
The joint in-house drug development program is expected to produce a broad range of novel drug candidates for HIV-1 integrase (Aids), HSP90 (oncology) and beta-secretase (Alzheimer's Disease) that will be marketed and out-licensed by both companies at the preclinical stage.
• Quantum Pharmaceuticals: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
